Literature DB >> 10618883

Max protein expression is associated with survival of children with lymphoblastic lymphoma.

Y Yuza1, M Kawakami, K Takagi, Y Yamazaki, M Urashima.   

Abstract

Overexpression of c-Myc in murine B lineage cells is associated with a polyclonal pre-B cell expansion as well as development of pre-B or B lymphoblastic lymphoma (LL) accompanied by leukemia, which mirrors the clinical features of childhood LL. Of interest, Max overexpression attenuates aberrant growth of B cells triggered by c-Myc. However, the clinical significance of Max in human lymphoid tissue remains to be clarified. In the present studies, we studied the expression of the c-Myc and Max proteins in normal lymph nodes and in childhood LL. In normal lymph nodes, c-Myc protein was expressed by the majority of cells in germinal center and marginal zone, but Max protein was expressed only by some of them. In contrast, c-Myc and Max were absent in mantle zone. Cells positive for c-Myc and Max expression in LL were 70.6 +/- 19.8% and 47.3 +/- 32.4%, respectively, determined by immunohistochemical staining using paraffin blocks from 23 cases of childhood LL. The survival of children with LL showing higher Max expression (> or = 30%) was significantly greater than that of lower expression (< 30%; P = 0.0027 using the Mantel-Cox test). These results suggest that Max protein may affect prognosis of childhood LL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10618883     DOI: 10.1046/j.1442-200x.1999.01140.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  2 in total

Review 1.  Pediatric non-Hodgkin's lymphoma: clinical and biologic prognostic factors and risk allocation.

Authors:  Sheila Weitzman; Kaveri Suryanarayan; Howard J Weinstein
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

2.  Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function.

Authors:  Hao Jiang; Kristen E Bower; Albert E Beuscher; Bin Zhou; Andrey A Bobkov; Arthur J Olson; Peter K Vogt
Journal:  Mol Pharmacol       Date:  2009-06-04       Impact factor: 4.436

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.